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Benign recurrent intrahepatic cholestasis (BRIC) is a rare disorder characterised by recurrent episodes of cholestatic jaundice.
First described in 1959, BRIC has been reported in patients all over the world including of African descent. Here, we describe a
case of a 21-year-old male with recurring episodes of cholestatic jaundice where we diagnosed BRIC and terminated an episode
with rifampicin. To our knowledge, this is the ﬁrst case report of BRIC diagnosed in Africa.

1. Introduction
Benign recurrent intrahepatic cholestasis (BRIC) is a rare,
autosomal recessive disorder characterised by recurrent,
self-limited episodes of cholestasis manifested by pruritus,
anorexia, fatigue, steatorrhea, and jaundice [1, 2]. The index
episode usually occurs in the ﬁrst two decades of life [2,3].
Episodes can be spontaneous or triggered by infections or
pregnancy and can last from weeks to months [2,4,5]. Diagnosis is based on a compatible clinical presentation,
laboratory parameters and histology with exclusion of other
causes of cholestasis [2] and conﬁrmed by genetic testing [1].
Treatment is supportive often aimed at relief of symptoms,
shortening of episodes, and prevention of complications [6].

2. Case
A 21-year-old male of Somali descent presented to our
institution in December 2018. He complained of pruritus for
a month and jaundice for two weeks. The pruritus was
severe, generalised, and worse at night. He also reported
fatigue, loss of appetite, dyspepsia, bloating, and right upper
quadrant discomfort associated with nonbilious vomiting.
His urine was dark and his stools loose, fatty, and pale. There
was recent easy bruising of the skin, but no mucous
membrane bleeding. He had lost 6 kilograms of weight since
onset of symptoms. He denied fever, arthralgia, myalgia, or

rash. He had no recent drug ingestion, risk factors for acquisition of viral hepatitis, food or drug allergies, and did not
smoke tobacco, consume alcohol, use injectionor inhaled
drugs.
He was the second-last born of 21 siblings and half siblings
and was unemployed. He reported no family history of cholestasis or liver disease. Several of his sisters were parous with
gestations uncomplicated by jaundice or pruritus.
On further questioning, he reported four similar prior
episodes over 7 years of varying severities lasting between
two to eight weeks with intervening symptom-free periods
(Table 1). These episodes were unprovoked except for two
occasions triggered by cutaneous infections. The episodes
followed a stereotyped pattern; the onset marked by loss of
appetite and severe generalised pruritus closely followed by
intense fatigue, bloating, right upper quadrant discomfort,
loose fatty stools, and dark urine. Scleral icterus characteristically developed two weeks later. Termination also
followed a typical pattern with sudden reduction, then
resolution of pruritus, a ravenous increase in appetite with
resolution of fatigue and other symptoms. Scleral icterus was
the last to resolve after a delay of two weeks. These episodes
were punctuated by a weight loss of 5-6 kilograms that was
regained back to baseline on recovery.
On examination, we found a lean young male with
scleral icterus and excoriation marks on his body. He was
alert and oriented in time, place, and person. There were no
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Table 1: Previous attacks.

Attack
1
2
3
4

Month, year
2014
June, 2016
April, 2017
December, 2017

Age at onset
14
16
17
18

Trigger (s)
None
Skin abscesses
None
Skin abscesses

stigmata of chronic liver disease. Abdominal examination
revealed mild right upper quadrant tenderness with a
negative Murphy’s sign, a normal liver span, and no clinically detectable ascites. The rest of the examination was
unremarkable.
His liver function tests revealed a cholestatic picture with
markedly elevated total bilirubin, predominantly direct.
Alkaline phosphatase was elevated to four times the upper
limit of normal, but gamma glutamyl transferase was normal, as were the transaminases. Prothrombin time was
prolonged with an INR of 1.98. Serology for hepatitis A, B,
and C and HIV 1&2 was negative. These results, along with
those from testing performed during the previous episodes
where he did not receive a diagnosis are charted in Table 2.
An abdominal ultrasound and magnetic resonance
cholangiopancreatography (MRCP) both revealed a normal
liver with normal biliary and pancreatic ducts. The patient
declined a liver biopsy due to ﬁnancial constraints at that
time. He was prescribed ursodeoxycholic acid, which he did
not take. The episode resolved spontaneously after seven
weeks, and follow-up liver function tests were subsequently
normal.
In June 2019, he presented 2 weeks into his sixth episode.
Laboratory testing again revealed a cholestatic picture with
peak total bilirubin 408 umol/l, direct bilirubin 326 umol/l,
alkaline phosphatase 688 U/L, GGT 7 U/L, and normal
transaminases. This time underwent a liver biopsy that
revealed preserved liver architecture without inﬂammation,
steatosis, or ﬁbrosis with intrahepatic cholestasis predominantly in the centrilobular zone (Figure 1).
Based on clinical, laboratory, and histologic ﬁndings, he
was diagnosed with BRIC as per the criteria proposed by
Luketic and Shiﬀman (Table 3). He was initiated on rifampicin 150 mg twice daily for a duration of two weeks with
rapid resolution of symptoms and improvement in biochemical parameters.

3. Discussion
BRIC, ﬁrst described in 1959 in two English patients, [7] has
since been reported to occur worldwide [2] including 4
patients of African descent in a 1989 case series from France
and Belgium [3] and recently in a North African teenager in
Switzerland [8]. While reports continue to emerge from
other parts of the world [8–11], there have been no reports of
cases diagnosed within Africa. This may be due to the rarity
of the condition compounded by a lack of awareness of
among clinicians.
Inheritance follows an autosomal recessive pattern with
mutations in both alleles of ATP8B1 (BRIC1) or ABCB11
(BRIC2) [1]. Both mutations cause cholestasis by impairing

Duration
2 weeks
7 weeks
8 weeks
5 weeks

Severity
Mild
Severe
Severe
Moderate

Period to next attack
2 years
7 months
6 months
11 months

the function of the bile salt export pump (BSEP), which
actively transports bile into canaliculi. ATP8B1 gene codes
for familial intrahepatic cholestasis type 1 transporter
(FIC1), a ﬂippase involved in translocation of phospholipids
across the plasma membrane. Deﬁciency of FIC1 decreases
plasma membrane stability, impairing the function of
transmembrane transporters including the BSEP, which is
encoded by ABCB11. Unlike the BSEP that is only expressed
in the canalicular membrane of hepatocytes, FIC1 is also
expressed in the small intestine and pancreas. This explains
why extrahepatic manifestations of BRIC1 such as diarrhoea
and pancreatitis are absent in BRIC2 [9].
Despite a genetic basis, most cases are sporadic. The ﬁrst
episode usually occurs in the ﬁrst two decades of life. Episodes can last from weeks to months and can be of varying
severity. In between episodes, patients remain totally devoid
of symptoms for periods ranging from months to years
[2, 3]. Triggers include stress, pregnancy, and airway and
gastrointestinal infections [2, 4, 10, 11]. Episodes triggered
by cutaneous infections seen in our patient have not been
described previously.
Pruritus and jaundice are the cardinal symptoms. Other
symptoms include malaise, right upper quadrant pain, anorexia, nausea, vomiting, steatorrhea, and weight loss [2].
Prolonged episodes can lead to coagulopathy and haemorrhagic tendencies due to vitamin K malabsorption [12].
Termination of the episodes is heralded by abrupt resolution
in anorexia and pruritus followed by gradual resolution in
jaundice. The symptoms vary from patient to patient but
remain consistent in the same individual across episodes [2].
Laboratory ﬁndings during episodes reveal an elevated
total bilirubin, which is predominantly direct. Alkaline
phosphatase is always elevated, sometimes markedly.
Transaminases are normal or mildly elevated but can also be
markedly elevated [3, 13]. Early ALT rise that eventually
resolves has also been described, a trend seen in our patient
during his second episode [4]. The hallmark of BRIC and the
other familial causes of intrahepatic cholestasis is that the
GGT is normal or only mildly elevated in comparison with
the other causes of intrahepatic cholestasis [2]. GGT release
is associated with damage to cholangiocytes caused by elevated toxic bile salts in bile. Impaired function of the BSEP
markedly reduces the concentration of bile salts in bile,
thereby explaining the low levels of GGT seen in these
conditions [1].
Liver biopsies performed during episodes reveal centrilobular cholestasis with bile deposition in canaliculi,
hepatocytes, and Kupﬀer’s cells. Hepatocyte degeneration,
necrosis, and portal and parenchymal inﬂammation may be
seen. These changes resolve completely between episodes
[2, 10].

±

0–21
0–3.4
52–171
2–42
0–50
0–50
60–85
35–55
Negative
Negative
Negative
Negative

4–10
45–75
25–40
2–10
1–6
0–2
4.5–6.5
40–54
13–18
150–400

Reference range

Negative
Negative

134.7
108.4
288.5
18.1
186.5
400.4

26/06/16
attack 2
7.04
65
26
7
2
0
5.46
50.6
16.4
369

Negative

229.1
204.9
313.0
8.0
60.7
62.4

09/07/16
attack 2

Antiliver kidney microsome type 1 antibody. ∗ ASMA, AMA-M2, M2-3E, SP-100, PML, gp210, LKM-1, LC-1, SLA/LP, and Ro-52.

White cell count (×109/L)
Neutrophils (%)
Lymphocytes (%)
Monocytes (%)
Eosinophils (%)
Basophils (%)
Red cell count (×1012/L)
Haematocrit (%)
Haemoglobin (g/dL)
Platelets (×109/L)
International normalised ratio (INR)
Total bilirubin (umol/L)
Direct bilirubin (umol/L)
Alkaline phosphatase (U/L)
Gamma glutamyl transferase (U/L)
Aspartate aminotransferase (U/L)
Alanine aminotransferase (U/L)
Total protein (g/L)
Albumin (g/L)
Hepatitis B surface antigen
Hepatitis A IgM antibody
Hepatitis A total antibody
Hepatitis C antibody
Antinuclear antibody
Antimitochondrial antibody
Anti-LKM A±
Liver antibodies∗

Investigation

Table 2: Laboratory results.

Negative
Positive

293.7
249.3
370.0
9.0
46.1
43.7

13/07/16
attack 2

Negative
Negative
Negative
Negative

07/01/18, 20/01/18
attack 4

Negative

1.98
393
337
692
12
48
32
91
46
Negative
Negative

04/12/18
attack 5
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(a)

(b)

Figure 1: Liver histology. (a) Liver architecture is preserved. No inﬂammation, steatosis, or ﬁbrosis seen (haematoxylin and eosin (H&E) ×
100). Intrahepatic cholestasis predominantly in the centrilobular zone is identiﬁed (black arrows). (b) Intrahepatic cholestasis (black arrows)
better demonstrated at a higher magniﬁcation (H&E × 400). Central vein at the middle.

Table 3: Diagnostic criteria.
Diagnostic criteria for BRIC (LUKETIC and SHIFFMAN, 2004)
At least two attacks of jaundice separated by a symptom-free
interval lasting several months to years
Laboratory values consistent with intrahepatic cholestasis
GGT either normal or only minimally elevated
Severe pruritus secondary to cholestasis
Liver histology demonstrating centrilobular cholestasis
Normal intra- and extrahepatic bile ducts by cholangiography
Absence of factors known to be associated with cholestasis (i.e.,
drugs and pregnancy)

Our case, the ﬁrst reported diagnosis of BRIC in Africa,
highlights the challenges faced in African countries in diagnosing such rare diseases, including lack of specialists and
availability and aﬀordability of diagnostic tests, ultimately
resulting in patients receiving delayed, wrong, or no diagnosis. It also adds to the literature on safety and eﬀectiveness
of rifampicin in therapy of BRIC episodes.
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